The nation of Zimbabwe has declined a substantial US health deal worth $367m (£272m) spanning five years because of the United States' request for confidential data.
This rejection became public after a government memo dated December was leaked, which showed President Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesperson has since clarified that the United States was seeking biological samples for research and commercial purposes but was unwilling to share the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate task of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for continued negotiations to reach a deal agreeable to all parties so the nation's critical HIV treatment initiative can continue.
Broader Context
This rejection comes after a similar situation in neighbouring Kenya, where a high court blocked a similar deal with the US following concerns were filed about the security of Kenyans' health data.
After resuming office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump stated its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
According to reports, Sixteen African countries have to date signed similar health pacts, constituting more than $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership could have provided immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on antiretroviral therapy through US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, with no equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," he stated.
"In essence, our country would provide the basic resources for medical research without any assurance that the end products would be accessible to our citizens should a new disease outbreak arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its pursuit of bilateral deals were upending systems previously established via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This system is intended to ensure that when a nation provides its samples, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We are open to ongoing dialogue with our US partners on how future co-operation could be designed in a manner that honours the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts said it acknowledged the government's concerns, but recommended that negotiations should continue given that much of the nation's Aids initiatives depended on foreign aid.
"Where specific concerns arise, including those relating to data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it added.
The halted deal underscores the continuing tensions between accepting vital foreign assistance and protecting a country's data in an ever more interconnected world.